300+ investors in your industry, stage, and region Get
Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Singapore
Oceania
LATAM
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Morocco
Seychelles
Paraguay
Botswana
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Ireland
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
ClavystBio, VC Fund

ClavystBio

VC Fund

Singapore, Singapore

ClavystBio is a VC fund in Singapore focused on Biotechnology and Health Care. ClavystBio invest in early-stage ventures in the biotech, medTech, and digital health sectors, as well as in real estate and services.

Total investments:
15
Last investment:
Lead investor:
53%

Last updated:

Industries ClavystBio invests in

BiotechnologyHealth CareMedicalTherapeuticsMedical Device

Stages ClavystBio invests in

Series AVenture - Series UnknownSeedSeries BSeries C

Countries ClavystBio invests in

SingaporeUnited StatesThe Netherlands

Round sizes

Series A $12M–$187MVenture - Series Unknown $14M–$25M

Contacts

NameEmailPhoneSocials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$12M–$187M
Venture - Series Unknown
$14M–$25M

Investment Focus

Industry

  • Biotechnology 10 (67%)
  • Health Care 8 (53%)
  • Medical 5 (33%)
  • Therapeutics 3 (20%)
  • Medical Device 2 (13%)
See all 17 industries →

Stage

  • Series A 5 (33%)
  • Venture - Series Unknown 3 (20%)
  • Seed 2 (13%)
  • Series B 2 (13%)
  • Series C 1 (7%)
See all 7 stages →

Country

  • Singapore 7 (47%)
  • United States 4 (27%)
  • The Netherlands 1 (7%)

Team

NameTitleInvestmentsLinksEmail
Sang Shin
Sang Shin Director, Digital Health
Director, Digital Health Total investments: 0
Find email

Investments

CompanyDescriptionRoundLinks
Leyden Labs Leyden Labs
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. $45.4M / Jun 25, 2026
Rejoni Rejoni
Rejoni uses bio-materials to develop medical devices that improve the outcome of minimally invasive and gynecological surgical procedures. $25M / Venture - Series Unknown / Jun 16, 2026
Biobot Surgical Pte Ltd Biobot Surgical Pte Ltd
Biobot Surgical is a global technology provider in minimally-invasive robotic healthcare solutions. $7.8M / Series C / Apr 09, 2026
Cirrus Therapeutics Cirrus Therapeutics
Cirrus Therapeutics is a Biotechnology Research firm diganosing and treating eye diseases affecting ocular immune system. $11M / Seed / Aug 19, 2025
Respiree Respiree
They offer platforms that are able to report clinical deterioration and provide recommended interventions with post-monitoring.They work in the health care industry, just like you. We take the time to get to know you, and we always keep your best interests in mind when adding and adjusting products in our catalog. $11.6M / Series A / Jul 23, 2025
Allay Therapeutics Allay Therapeutics
Allay Therapeutics offers analgesic products for post-surgical pain management and recuperation. The company was founded in 2017 and is headquartered in Menlo Park, California, United States. $57.5M / Series D / Jun 05, 2025
Nuevocor Nuevocor
Nuevocor is a preclinical-stage biopharmaceutical company focused on developing gene therapy‑based treatments that have the potential to restore cardiac function in diseased hearts. $45M / Series B / May 06, 2025
Callio Therapeutics Callio Therapeutics
Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits. $187M / Series A / Mar 03, 2025
Leyden Labs Leyden Labs
Leyden Labs aims to help people live their lives to the fullest. Its platform targets commonalities of viral families to protect humanity from known and future viruses. Its portfolio of accessible intranasal product candidates may provide people with the freedom to immediately protect themselves from and prevent the spread of many strains ofrespiratory viruses, including ones in the influenza and coronavirus families. The Company’s energetic team of world-renown biotechnology veterans and fresh talent is dedicated to thinking differently to free humanity from the burden of respiratory viruses. $70M / Series B / Jan 09, 2025
Sunbird Bio Sunbird Bio
Sunbird Bio is a diagnostics platform developer that aims to give molecular diagnostics with faster outcomes. Sunbird Bio was founded by Huilin Shao. $14M / Venture - Series Unknown / Oct 16, 2024
See all 15 investments →

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Big Data
Video Games
Clean Energy
Google
Construction
Hospitality
EdTech
Consumer
Artificial Intelligence
Local
Enterprise Software
Platforms
Travel
InsurTech
Oil and Gas
Retail
Social Impact
Cryptocurrency
Film
Payments
Photography
Email
CleanTech
Energy
Marketplace
SaaS
Restaurants
Organic Food
Fitness
Machine Learning
Health Care
Agriculture (AgTech)
Gaming
Facebook
Blockchain
B2B
Social Network
Education
Wellness
Medical Device
Mobile
Sports
Legal
Automotive
eSports
Biotechnology
Software
Renewable Energy
Theatre
Crowdfunding
Recruiting
Web3
Medical
Infrastructure
Beauty
Fashion
Venture Capital
Social
LGBT
Cannabis
Climate
Celebrity
Wine and Spirits
Food and Beverage
Publishing
Life Science
Mobile Apps
Music
Real Estate
Sporting Goods
Art
Digital Media
FinTech
Manufacturing
Finance
Financial Services
Social Media
Franchise
Mobile Advertising
Non Profit
Internet
Android
Biotech
Sustainability
Transportation
Proptech
Impact
Hardware
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
United Kingdom
Hong Kong
Thailand
United Arab Emirates
Greece
Benin
Croatia
Japan
South Korea
Burkina Faso
Africa
Brazil
Gibraltar
Egypt
Kyrgyzstan
Zambia
Zimbabwe
Sweden
Taiwan
Norway
Tajikistan
Tunisia
Liberia
Malawi
Mexico
Nigeria
Russian Federation
Togo
Nepal
Guinea
Haiti
Iran
Isle of Man
Lesotho
Madagascar
Pakistan
Romania
Singapore
Oceania
LATAM
Oman
Puerto Rico
Poland
Guernsey
Cameroon
Andorra
Colombia
Sudan
Armenia
China
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Namibia
Mozambique
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Australia
Saudi Arabia
Sri Lanka
Jamaica
Switzerland
Guatemala
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Moldova
Morocco
Seychelles
Paraguay
Botswana
Canada
South Africa
France
Georgia
Denmark
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
Senegal
El Salvador
Tanzania
India
Germany
United States
Indonesia
Middle East
Bermuda
Dominican Republic
Asia
Albania
Qatar
Spain
Angola
Europe
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Bulgaria
Ecuador
Estonia
Faroe Islands
Jersey
Bahrain
Bahamas
Bolivia
Belize
Algeria
Italy
Finland
Belarus
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Ireland
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does ClavystBio invest in?

ClavystBio invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Venture - Series Unknown stage. Most of the 15 investments tracked by Shizune back companies in Singapore. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What is ClavystBio's check size?

ClavystBio typically joins rounds of $12M–$187M at Series A and $14M–$25M at Venture - Series Unknown. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds ClavystBio participates in.

How do I contact ClavystBio?

Public channels for ClavystBio include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

Who are the partners at ClavystBio?

The team at ClavystBio includes Sang Shin (Director, Digital Health). The Team section lists each member with their title, investment count and links.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
ClavystBio ClavystBio Find emails